PARP inhibitor chemical series

PARP inhibitorRefresh recommended

Nicotinamide mimic pharmacophore to olaparib, niraparib, rucaparib and talazoparib.

Mechanism · PARP inhibitor BioMoa · PARP inhibitor BioMoa bridge · shared ID

Last analysis: 7/20/2026, 2:09:34 AM · 2 weeks cadence · refresh on /analyze · refresh recommended

Data sources: Catalog seed · PubChem · ChEMBL · ClinicalTrials.gov · FDA/EMA
Last updated: 7/20/2026, 2:09:34 AM
Similarity method: Morgan fingerprint, radius 2, 2048 bits, Tanimoto
Verified / known compounds: 4
Exploratory nodes: 2
Abstract scaffolds: 1
Relationship types: Derived (curated) · Fingerprint similarity · Drug-class link

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Spider Web · Flow · Structure table · Compare · SMILES map

Name, 2D structure, SMILES, role, parent, core similarity, and traits. Click a row for details.

Compound	Role	SMILES	Parent	Core sim.	Traits
PARP nicotinamide pharmacophoreAbstract pharmacophoreparp-nicotinamide-corePage	Scaffold	`NC(=O)c1cccnc1`	—	—	PARP · core · Shared pharmacophore / core scaffold. Anchor for the PARP inhibitor chemical series lineag…
Niraparib (Zejula)Verified drugniraparibPage	Drug	`C1=CC(=CC=C1C2=CC=CC=C2C(=O)NC3=CC=C(C=C3)…`	PARP nicotinamide pharmacophore	16%i	approved · PARP · Approved therapeutic. Niraparib (Zejula) in this family map. · CHEMBL2103875 · CID 24958200
Olaparib (Lynparza)Verified drugolaparibPage	Drug	`CC1=CC(=CC(=C1)C2=CC(=CC=C2)C(=O)N3CCCC3)C…`	PARP nicotinamide pharmacophore	28%i	approved · PARP · PARP1/2 inhibitor — synthetic lethality in BRCA-mutant tumors. · CHEMBL521686 · CID 23725625
Rucaparib (Rubraca)Verified drugrucaparibPage	Drug	`CCC1=CC(=CC(=C1NC(=O)C2=CC=CC(=C2)F)C)C(=O…`	PARP nicotinamide pharmacophore	13%i	approved · PARP · Approved therapeutic. Rucaparib (Rubraca) in this family map. · CHEMBL2016775 · CID 9931953
Talazoparib (Talzenna)Verified drugtalazoparibPage	Drug	`CN1C2=NC(=NC2=CC=C1C(=O)NC3=CC(=C(C=C3)C(F…`	PARP nicotinamide pharmacophore	10%i	approved · PARP · Approved therapeutic. Talazoparib (Talzenna) in this family map. · CHEMBL3137336 · CID 135565082
PARP fluoro-aryl analogExploratory analog (rule-generated)parp-sar-fluoroPage	Derivative	`CC1=CC(=CC(=C1)C2=CC(=CC=C2)C(=O)N3CCCC3)C…`	PARP SAR indole analog	15%i	SAR · F-scan · SAR exploration node. Derived analog of parent node in PARP inhibitor chemical series.
PARP SAR indole analogExploratory analog (rule-generated)parp-sar-indolePage	Derivative	`CC1=CC(=CC(=C1)C2=CC(=CC=C2)C(=O)N3CCCC3)C…`	Olaparib (Lynparza)	14%i	SAR · SAR exploration node. Derived analog of parent node in PARP inhibitor chemical series.

Name	Role	Derived from	Sim. to core	Relations	Tags
Niraparib (Zejula)Verified drug	Drug	PARP nicotinamide pharmacophore	16%i	derived_from: PARP nicotinamide pharmacophore · similar_to: Olaparib (Lynparza) · related_drug: Olaparib (Lynparza) · similar_to: PARP nicotinamide pharmacophore	approved, PARP
Olaparib (Lynparza)Verified drug	Drug	PARP nicotinamide pharmacophore	28%i	derived_from: PARP nicotinamide pharmacophore · derived_from: PARP SAR indole analog · similar_to: Niraparib (Zejula) · related_drug: Niraparib (Zejula) · similar_to: PARP nicotinamide pharmacophore · similar_to: PARP fluoro-aryl analog · similar_to: PARP SAR indole analog	approved, PARP
PARP SAR indole analogExploratory analog (rule-generated)	Derivative	Olaparib (Lynparza)	14%i	derived_from: Olaparib (Lynparza) · derived_from: PARP fluoro-aryl analog · similar_to: PARP nicotinamide pharmacophore · similar_to: Olaparib (Lynparza) · similar_to: PARP fluoro-aryl analog	SAR
PARP fluoro-aryl analogExploratory analog (rule-generated)	Derivative	PARP SAR indole analog	15%i	derived_from: PARP SAR indole analog · related_drug: Talazoparib (Talzenna) · similar_to: PARP nicotinamide pharmacophore · similar_to: Olaparib (Lynparza) · similar_to: PARP SAR indole analog	SAR, F-scan
PARP nicotinamide pharmacophoreAbstract pharmacophore	Scaffold	—	—	derived_from: Olaparib (Lynparza) · derived_from: Niraparib (Zejula) · derived_from: Rucaparib (Rubraca) · derived_from: Talazoparib (Talzenna) · similar_to: Olaparib (Lynparza) · similar_to: Rucaparib (Rubraca) · similar_to: PARP SAR indole analog · similar_to: Niraparib (Zejula) · similar_to: Talazoparib (Talzenna) · similar_to: PARP fluoro-aryl analog	PARP, core
Rucaparib (Rubraca)Verified drug	Drug	PARP nicotinamide pharmacophore	13%i	derived_from: PARP nicotinamide pharmacophore · similar_to: Talazoparib (Talzenna) · related_drug: Talazoparib (Talzenna) · similar_to: PARP nicotinamide pharmacophore	approved, PARP
Talazoparib (Talzenna)Verified drug	Drug	PARP nicotinamide pharmacophore	10%i	derived_from: PARP nicotinamide pharmacophore · similar_to: Rucaparib (Rubraca) · related_drug: Rucaparib (Rubraca) · related_drug: PARP fluoro-aryl analog · similar_to: PARP nicotinamide pharmacophore	approved, PARP

Loading map…

Clinical · regulatory context

PARP — HRD / BRCA

Olaparib 등. 혈액독성·MDS/AML 경고가 class 이슈입니다.

Approved/clinical labels here come from the catalog clinical overlay. Agency names are shown when curated; live FDA/EMA APIs are not called.

OlaparibApprovedFDA/EMA
BRCA/HRD tumors (ovarian, breast, prostate, pancreas)
ClinicalTrials.gov

Program and pipeline notes live on BioMoa · parp · StructureMoa ↔ BioMoa bridge